Inclusion Criteria:
  -  Children and adolescents who are diagnosed with pediatric chronic severe plaque psoriasis.
  -  Prior to participating in the study, adalimumab treatment was determined according to clinical judgement of the physician.
  -  Participants (or legal representative) who voluntarily agreed to participate in this study and signed informed consent.
Exclusion Criteria:
  -  Participants with contraindication to adalimumab as listed in the approved Korean label.
  -  Participants with prior treatment with adalimumab.